Programs & products | Innate Pharma

First-in-class CD39 checkpoint inhibitor presented at the AACR meeting

April 19, 2016

Novel, potent anti-CD39 antibody, IPH52, validated in preclinical models. Innate Pharma and OREGA Biotech today presented preclinical data on IPH52, a new CD39 checkpoint inhibitor program, at the...

New data presented at AACR support the rationale for combination treatment with monalizumab and durvalumab

April 18, 2016

Preclinical data demonstrate enhanced anti-tumor efficacy by combining PD-1/PD-L1 pathway blockade and NKG2A checkpoint inhibitor; Resistance to PD-1 pathway blockers is associated with upregulation...

Innate Pharma presents new CD73 checkpoint inhibitor program

April 18, 2016

Novel antibodies identified that block the CD73 immune checkpoint for cancer immunotherapy; Strengthens Innate’s positioning in targeting the tumor microenvironment. Innate Pharma SA (the “Company” -...

New preclinical data further supporting the development of IPH4301 presented at the AACR meeting

April 18, 2016

First-in-class anti-MICA/B therapeutic antibody; New data demonstrate dual mechanism of action of IPH4301, including tumor antigen targeting and immunomodulation; IND-enabling studies starting in 2016...

AACR 2016: Innate Pharma displays broad innovative pipeline in immuno-oncology

March 17, 2016

Five posters presented by Innate Pharma and collaborators; New data further supporting the rationale of four of Innate’s clinical and preclinical programs; New checkpoint inhibitor program targeting...

Sixth data and safety monitoring board meeting of the EffiKIR trial recommends continuation without modification

March 16, 2016

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the Data and Safety Monitoring Board (“DSMB”) completed its sixth assessment of the EffiKIR study and...

Start of Phase I clinical trial of monalizumab in combination with durvalumab

February 8, 2016

Multicenter, open-label, dose-escalation and cohort-expansion Phase I study of durvalumab in combination with monalizumab in patients with solid tumors; Trial performed by AstraZeneca/MedImmune in the...

Sanofi and Innate Pharma Collaborate on New Bispecific NK Cell Engagers in Immuno-Oncology

January 11, 2016

Research collaboration and licensing agreement for new bispecific antibodies using Innate Pharma’s technology and Sanofi’s technology and tumor targets Innate Pharma eligible for up to €400m in...

Innate Pharma in-licenses OREGA biotech's first-in-class anti-CD39 checkpoint inhibitor program

January 10, 2016

This program, currently in preclinical development, aims at developing an anti-CD39 mAb; Targeting the adenosine immunosuppressive pathway has potential to promote anti-tumor immune responses across a...

IPH5201

What is IPH5201?

IPH5201 is a blocking antibody targeting the CD39 immunosuppressive pathway.
CD39 is an extracellular membrane-bound enzyme that is expressed on both tumor infiltrating immune cells and stromal cells, in several cancer types.

Read more about IPH5201

Subscribe to Programs & products

Company
Science
Products
- Pipeline overview
- ------------------
- Lacutamab
- IPH4502
- Monalizumab
- Other Clinical Stage Assets
  - IPH6501
  - IPH6101
  - IPH6401
  - IPH5201
  - IPH5301
Partnering
Investors
Media
Careers